Galmed Pharmaceuticals Ltd (GLMD)

[aristotelisonassis]

in here. very cheap. long!

[DewDiligence]

G. Yarom Medical Research owned a 27.3% equity stake as of 12/31/17:

https://www.sec.gov/Archives/edgar/data/1595353/000114420418004035/tv483844_sc13ga.htm

[Sampson001]

I'm up fairly well here, hoping for some positive results soon !!!

[DewDiligence]

There's a lot of anticipation regarding the NASH data to be released from two studies during the current quarter.

[noretreat]

stock is flying! found out about at the showcase 2 years ago.

[DewDiligence]

GLMD—Latest corporate slides:

https://www.sec.gov/Archives/edgar/data/1595353/000114420418000341/tv482490_ex99-1.htm

[DewDiligence]

GLMD had $19.0M of cash at 12/31/17 thanks to ATM sales during December (at relatively high prices):

https://www.sec.gov/Archives/edgar/data/1595353/000114420418000046/tv482405_ex99-1.htm

Galmed Pharmaceuticals…today announced it raised approximately $11.6 million in gross proceeds during December 2017 under the Company’s at-the-market (“ATM”) programs. The Company issued 1,368,667 ordinary shares under its former and existing ATM programs during December 2017 at an average sale price of $8.45 per share.

…Based on preliminary unaudited financial information, as of December 31, 2017, Galmed has cash and cash equivalents and marketable securities of approximately $19.0 million.

This is more than enough cash to carry GLMD to the data readout of the phase-2/3 ARREST trial in NASH, expected in 1Q18.

[puravida]

Dew I've been looking into the NAFLD/NASH arena too while I agree with you on the ENTA long hold I'm surprised you haven't nibbled at this. is it the cash position? the lower than expected funds raised at the end of summer? or are you more cautious of the mechanism behind the science? I do wish this co had more cash position IMO

[DewDiligence]

GLMD’s pro forma cash=$10.1M—including $1.1M raised via the ATM since 9/30/17:

https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-reports-third-quarter-2017-financial-results-and-provides-business-update-300551897.html

[DewDiligence]

No GLMD position; I'm long ENTA and keenly watching the NASH arena.

[Sampson001]

Seems to be a lot of accumulation as of late.....results are due in early 2018. I'm loaded, RU ?

[DewDiligence]

GLMD -15%/AH on sale of 381K shares @$7.10 in registered direct offering (of which insiders are buying 49K shares):

http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-announces-pricing-of-offering-of-ordinary-shares-to-existing-investors-and-members-of-the-board-of-directors-300499533.html

The selloff in AH trading is presumably due to the fact that the company was able to raise only $2.7M (gross proceeds) from this offering. They need more.

[Sampson001]

The news is finally leaking out.....they presented impressive information last month at the Nash event in Holland. People are just coming around to this. GLMD is a very small company, so it takes a while for anything good to get in the ears of people. There will be a buy out before years end. G/l to all

[DewDiligence]

No news that I'm aware of.

[aintitahoot]

Stock has been perking up a bit, may be nothing of substance but still a very quiet board.

[Sampson001]

This is going to be a very big weekend coming up for GLMD. Big presentation in Holland.....watch for alot of band wagon buying after next weekend !!!!

[DewDiligence]

GLMD had only $12.2M net current assets at 12/31/16:

https://www.sec.gov/Archives/edgar/data/1595353/000114420417016148/v462263_20f.htm#f_002

[Sampson001]

Currently above the 2o, 50 and 100 day moving average. Me thinks there will be a little run here. Results due in June of 2017. If this is positive, we will see 15 - 17 bucks per share

[Sampson001]

Earnings report Monday am !!!

[noretreat]

This stock should be headed significantly higher in 2017. It is on my "buy the dips" list.

[biotechnician]

Major NASH news from BLRX

Pre-clinical results obtained in animal models of liver impairment suggest that BL-1220 has strong hepato-protective effects. Collectively, the data demonstrate that BL-1220 is able to restore liver function. This technology could be directed toward rapid regeneration of normal liver in both acute and chronic conditions of liver injury.

Philip Serlin, Chief Financial and Operating Officer of BioLineRx, said, "In August this year, we in-licensed the first compound under our multi-year strategic partnership with Novartis, a novel drug candidate for controlling liver fibrosis through modulation of the immune system. Today, we are pleased to announce the second compound under the Novartis collaboration, also for the treatment of liver pathologies. Both of these projects fit our strategic focus on the immunology space. We continue to work closely with Novartis to identify cutting-edge, novel therapies and we expect to bring additional promising projects to the collaboration by the end of the year."

[Logger007]

New life..

[DewDiligence]

GLMD on Nasdaq trades <$200K worth of stock on an average day.

[Sampson001]

Why didn;t this trade for the first half ?

[DewDiligence]

1Q16 PR/CC leave questions re liquidity/cash burn: #msg-122681999.

[Sampson001]

Just read an article stating that Biotech's are lagging and to get ready for them to roll....do we count as a BIOTECH ?

[Sampson001]

Thank you for the link to the financials from GLMD....$23 mill is more than what I read they had, I did read they'll be good till mid 2017 ? ...There should be a completed study of phase 2 by then. I think its called "Arrest" and that should be positive. A nice S/P jump due to those results would be a good time to do what ever they need to do to then increase their cash. I see you've got 90,000 plus posts...certainly don't have the time to read what you've posted to gauge your knowledge, I'm pretty sure yours FAR exceeds mine...I'm just more of an occasional investor willing to make a gamble here and there....it just seemed to me that GLMD was one that in time would pay off. 2000 shares in 5 years I'm hoping will turn out as a fairly nice reward. Any guidance / knowledge you share will be most appreciated.

[DewDiligence]

I replied in #msg-121799257.

[Sampson001]

Not sure GLMD will have cash by then....they'll have to resort to some type of dilution to create more cash.....

[noretreat]

interesting...wish I'd been holding more (of course)

http://seekingalpha.com/news/3171773-gilead-takeout-nimbus-stokes-buying-nash-players?app=1&uprof=45#email_link

[noretreat]

This company has an interesting approach.

I think there is high potential....

[DewDiligence]

Final phase-2/3 NASH data pushed back to 3Q17: #msg-116252542.

[DewDiligence]

2Q15 CC link:

https://www.webcaster4.com/Webcast/ListenPage?companyId=935&webcastId=10064

I couldn’t find the link on the company’s website, so I got it from IR.

[DewDiligence]

GLMD had $27.8M of cash at 6/30/15—a burn of $2.1M during 2Q15:

http://finance.yahoo.com/news/galmed-pharmaceuticals-announces-commencement-patient-114500880.html

GLMD claims the cash balance is enough to last “into 2017,” but that seems like a stretch. The company has a $150M shelf registration (#msg-112291490).

[DewDiligence]

GLMD seeks blood-based companion diagnostic for Aramchol NASH program:

http://finance.yahoo.com/news/galmed-pharmaceuticals-unfolds-development-aramchol-121100250.html

[DewDiligence]

GLMD cited in Medscape overview of NASH therapeutics: #msg-112427795.

[stocktrademan]

$GLMD recent news/filings

bullish
bounce off moving average

## source: finance.yahoo.com

Fri, 10 Apr 2015 22:06:00 GMT ~ Nasdaq stocks posting largest percentage increases

[AP] - A look at the 10 biggest percentage gainers on Nasdaq at the close of trading: Tonix Pharma rose 26.5 percent to $7.40. Trillium Therapeutic rose 16.4 percent to $11.12. Ebix Inc. rose 14.3 percent to ...

read full: http://sg.finance.yahoo.com/news/nasdaq-stocks-posting-largest-percentage-220237991--finance.html
*********************************************************

Sat, 04 Apr 2015 17:04:08 GMT ~ GALMED PHARMACEUTICALS LTD. Financials


read full: http://finance.yahoo.com/q/is?s=glmd&annual
*********************************************************

Wed, 01 Apr 2015 15:20:01 GMT ~ Biotechs Raising New Capital in Droves


read full: http://247wallst.com/healthcare-business/2015/04/01/biotechs-raising-new-capital-in-droves/
*********************************************************

Wed, 01 Apr 2015 12:00:00 GMT ~ Galmed Pharmaceuticals Announces the Appointment of George Tonelli as Vice President of Clinical Operations

[PR Newswire] - TEL AVIV, Israel, April 1, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced that it has appointed George Tonelli as Vice President of Clinical Operations. Mr. Tonelli brings 20+ years of progressive experience in clinical operations, development and regulatory affairs. From 2005 to 2014, Mr. Tonelli planned and executed multiple clinical trials in the therapeutic area of Diabetes Mellitus at MannKind Corporation, culminating in the FDA approval of Afrezza®. Prior to MannKind, Mr. Tonelli held several leadership positions in clinical development and project management at Innapharma. Mr. Tonelli began his career in regulatory affairs in the Medical Research Division of American Cyanamid (Lederle Labs).

read full: http://finance.yahoo.com/news/galmed-pharmaceuticals-announces-appointment-george-120000463.html
*********************************************************

Tue, 31 Mar 2015 12:00:00 GMT ~ Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update

[PR Newswire] - TEL AVIV, Israel, March 31, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization ...

read full: http://finance.yahoo.com/news/galmed-pharmaceuticals-reports-full-2014-120000693.html
*********************************************************

$GLMD charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$GLMD company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/GLMD/company-info
Ticker: $GLMD
OTC Market Place: Not Available
CIK code: not found
Company name: Galmed Pharmaceuticals Ltd.
Incorporated In: USA

$GLMD share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: l PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">; OTC Markets | Official site of the OTCQX, OTCQB and OTC Pink Marketplaces featuring Free Stock & Bond Quotes, Trade Prices, Chart, Financials and Company News & Information for Investors, Companies and Traders - OTCMarkets.com var appSection = "" ; var tierGroupId = undefined; var symbol = "GLMD"; var jq191 = $.noConflict(true); var appNav = new OTCMarketsAppNav(); var iqCaller = new OtcIQCalls(); var commonCaller = new PinkCommonCalls(); var contentCaller = new PinkContentCalls(); var edgarCaller = new PinkEdgarCalls(); var decorateSymbols = new SymbolDecorator(commonCaller); height="0" width="0" style="display:none;visibility:hidden"> (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= '//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer',"GTM-N65JXN"); OTC Markets Home Marketplaces Market Activity Current Market Closing Summary Broker Dealer Data Corporate Actions Short Sale Data Reg SHO Data News Company News & Financials Press Releases Videos & Presentations RSS Feeds OTC Markets Events OTC Markets Newsletter OTC Markets Press Center Services Companies Investors Market Data Trading Research Stock Screener OTCQX Company List Company Directory Service Provider Directory OTCQX Advisor List Broker Dealer Directory Prohibited Attorney List Symbology Glossary Learn Our Marketplaces Market 101 Investor Protection Reporting Requirements American Depositary Receipts (ADRs) Apply for OTCQX - Our Best Marketplace Comply with New OTCQB Requirements Information for OTC Pink Companies How to Get Traded Caveat Emptor Policy FINRA & SEC Rules Whitepapers FAQs tierTitle = getTierTitle(undefined); Company Directory | Stock Screener OTC Market Totals - Securities - Dollar Volume - Share Volume - Trades var glossaryDecorator = new GlossaryDecorator (contentCaller) ; $('p').each (function () { var glossaryId = $(this).attr('glossaryId'); if (glossaryId) this.psGlossaryId=glossaryId; }); if (document.getElementById('p')) glossaryDecorator .doSection (document.getElementById ('p')); $('#quoteEntry input#quoteBox').focus(function() { toggleFieldValue(this, 'Enter Symbol/Company Name', ''); }).blur(function() { toggleFieldValue(this, '', 'Enter Symbol/Company Name'); }); var security = new SecurityInfo(233186, 681810, "Galmed Pharmaceuticals Ltd.", "GALMED PHARMA", "GLMD", "Nasdaq", false, false, undefined, "Common Stock", undefined, undefined, false, false, true, false, undefined, undefined, undefined, false, 1.0, undefined); var symbolSecurity = (security.symbol)? security.symbol:security.secId; var initNewsId = undefined; var glossaryDecorator = new GlossaryDecorator (contentCaller) ; Quote Charts Company Profile News Financials Filings and Disclosure Short Sales Insider Disclosure Research Reports Videos and Presentations GLMD Galmed Pharmaceuticals Ltd. Common Stock Nasdaq function doOTCQX30Logo(url) { var CONSTITUENTS_DATA; if ($.browser.msie) { var http = new XDomainRequest(); http.open("get", url); http.onload = function() { var data = http.responseText; if (typeof data === "undefined") return; CONSTITUENTS_DATA = JSON.parse(data); displayIndexLogo(CONSTITUENTS_DATA); }; http.send(null); } else { $.ajax({ type : "GET", url : url, data : {}, success : function(data) { if (typeof data === "undefined") return; CONSTITUENTS_DATA = JSON.parse(data); displayIndexLogo(CONSTITUENTS_DATA); } }); } } function displayIndexLogo(constituents) { if (typeof constituents === undefined) { if (console && console.log) { console.log("Unable to load constituents."); } } var result = $.grep(constituents, function(e){ return e.ticker == security.symbol; }); if (result.length > 0) { $('.tierLogoContainer a').attr('href', '/index/.OTCQX30/quote'); $('.tierLogo').attr('src', '/content/doc/otcm/tier/logo/small/otcqx30.png'); $('.tierLogo').attr('alt','OTCM QX ADR 30 Index Constituent'); $('.tierLogo')[0].psGlossaryId='otcqx30-constituent'; handler.decorateGlossary(); } } var json_url = "http://s3.amazonaws.com/content.otcmarkets.com/constituents/otcqx_30_list.json";; doOTCQX30Logo(json_url); var handler = new QuoteHandler(); handler.checkCaveat(); var tradeHeaderHandler; if (!window.location.href.match('quote')) tradeHeaderHandler = new TradeHeaderHandler(iqCaller, window.document.getElementById('quoteBar')); if (security.symbol == null || security.symbol.length == 0) { $('#quoteUnderArrowTabs li.eqOnly').hide(); } $('img').each(function () { var glossaryId = $(this).attr('glossaryId'); if (glossaryId) this.psGlossaryId = glossaryId; }); handler.decorateGlossary(); $("#title").html('Company Info'); var shortDesc = undefined; var longDesc = undefined; function toggleFullDescription(full) { if (full) { $("#businessContent p").html(longDesc); }else { $("#businessContent p").html(shortDesc); } } Contact Info Business Description Not Available Update Company Profile Financial Reporting/Disclosure Reporting Status Alternative Reporting Standard
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$GLMD extra dd links

Company name: Galmed Pharmaceuticals Ltd.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=GLMD+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=GLMD+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=GLMD+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/GLMD/news - http://finance.yahoo.com/q/h?s=GLMD+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/GLMD/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/GLMD/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=GLMD+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/GLMD
DTCC (dtcc.com): http://search2.dtcc.com/?q=Galmed+Pharmaceuticals+Ltd.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Galmed+Pharmaceuticals+Ltd.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Galmed+Pharmaceuticals+Ltd.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/GLMD
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/GLMD/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/GLMD/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=GLMD&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=GLMD
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/GLMD/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=GLMD+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=GLMD+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=GLMD
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=GLMD
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=GLMD+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/GLMD/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=GLMD+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/GLMD.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=GLMD
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/GLMD/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/GLMD
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/GLMD
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/GLMD:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=GLMD
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=GLMD



$GLMD DD Notes ~ http://www.ddnotesmaker.com/GLMD

[DewDiligence]

GLMD hires CMO:

http://finance.yahoo.com/news/galmed-pharmaceuticals-announces-appointment-george-120000463.html

[DewDiligence]

$150M shelf registration:

http://www.sec.gov/Archives/edgar/data/1595353/000114420415020121/v405749_f3.htm

[DewDiligence]

Brief notes on 4Q14 CC: #msg-112273066.

[bobbytx1]

BAAAAAAAAAAAAM 2 $$$$$$$$$$$$$$$$$$$$$$$$$

[Kraken3]

BAMMMMMMM!!!!!!